Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 93.8%

Neg 0% Neu 0% Pos 93.8%

Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy and raises the price target from $7 to $9.